SWS Partners Has $1.79 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

SWS Partners reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report) by 1.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,402 shares of the pharmaceutical company’s stock after selling 72 shares during the quarter. SWS Partners’ holdings in Vertex Pharmaceuticals were worth $1,791,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Norges Bank bought a new stake in Vertex Pharmaceuticals in the fourth quarter worth approximately $1,237,877,000. abrdn plc increased its holdings in shares of Vertex Pharmaceuticals by 196.0% during the fourth quarter. abrdn plc now owns 581,018 shares of the pharmaceutical company’s stock valued at $236,410,000 after acquiring an additional 384,730 shares in the last quarter. BSN CAPITAL PARTNERS Ltd bought a new stake in shares of Vertex Pharmaceuticals during the fourth quarter valued at approximately $81,378,000. Jennison Associates LLC increased its holdings in shares of Vertex Pharmaceuticals by 3.9% during the fourth quarter. Jennison Associates LLC now owns 3,944,913 shares of the pharmaceutical company’s stock valued at $1,605,146,000 after acquiring an additional 147,248 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Vertex Pharmaceuticals by 4.9% during the third quarter. Northern Trust Corp now owns 2,813,563 shares of the pharmaceutical company’s stock valued at $978,388,000 after acquiring an additional 131,539 shares in the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Piper Sandler boosted their price objective on Vertex Pharmaceuticals from $450.00 to $456.00 and gave the company an “overweight” rating in a report on Tuesday, May 7th. Needham & Company LLC reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 7th. William Blair reiterated an “outperform” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, February 6th. Royal Bank of Canada upped their price target on Vertex Pharmaceuticals from $417.00 to $424.00 and gave the stock a “sector perform” rating in a report on Tuesday, May 7th. Finally, Barclays upped their price target on Vertex Pharmaceuticals from $446.00 to $472.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $438.62.

Get Our Latest Stock Report on VRTX

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ VRTX traded up $13.16 during trading on Monday, reaching $468.50. 546,626 shares of the stock traded hands, compared to its average volume of 1,215,374. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.50 and a quick ratio of 3.29. Vertex Pharmaceuticals Incorporated has a 52-week low of $323.02 and a 52-week high of $468.63. The stock has a market capitalization of $120.90 billion, a P/E ratio of 29.55, a price-to-earnings-growth ratio of 2.34 and a beta of 0.41. The company has a 50-day moving average of $416.95 and a 200-day moving average of $409.83.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last released its quarterly earnings data on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.66 by $1.10. Vertex Pharmaceuticals had a return on equity of 23.08% and a net margin of 39.46%. The company had revenue of $2.69 billion for the quarter, compared to analyst estimates of $2.58 billion. During the same period in the previous year, the company posted $2.67 EPS. The firm’s revenue for the quarter was up 13.3% compared to the same quarter last year. Analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.22 EPS for the current fiscal year.

Insider Activity at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs sold 7,073 shares of the business’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $448.00, for a total transaction of $3,168,704.00. Following the sale, the director now directly owns 40,000 shares in the company, valued at approximately $17,920,000. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Vertex Pharmaceuticals news, CEO Reshma Kewalramani sold 1,565 shares of the company’s stock in a transaction dated Friday, May 24th. The stock was sold at an average price of $457.00, for a total value of $715,205.00. Following the transaction, the chief executive officer now directly owns 121,374 shares in the company, valued at approximately $55,467,918. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bruce I. Sachs sold 7,073 shares of the company’s stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $448.00, for a total value of $3,168,704.00. Following the completion of the transaction, the director now owns 40,000 shares in the company, valued at $17,920,000. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,168 shares of company stock worth $6,377,853. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Company Profile

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

See Also

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.